Table of Contents :
• Stock Rating & Target Price
• Investment Thesis
• Fundamental Models Used
• Company Description
• Corporate Timeline
• Key Metrics (KPI ) and Recently Reported Earnings Review
• Business Highlights, Strategic Announcements & Outlook
• Quarter-over-Quarter (Q-o-Q) and Year-over-Year (Y-o-Y) Growth Analysis
• Key Catalysts Driving Growth
• Historical Financial Statement Analysis & CAGR Trends
• Quarterly Key Financial Ratios and Performance Metrics
• Annual Financial Performance Analysis: Horizontal and Vertical Financial Analysis, Trends
• Financial Forecasts
• Annual Forecasts: Income Statement
• Annual Forecasts: Cash Flow Statements
• Net Debt Levels
• A Closer Look at DCF: Our Assumptions and Methodology
• Terminal Value Calculation
• Target Price Analysis
• Valuation Multiples
• Supplementary Valuation Analysis: Multiples Approach
• Scenario/Sensitivity Analysis – Base Case , Bull Case ,Bear Case
• Holistic Peer Review & Trading Comps: Financial Data, Operational Metrics, and Valuation Multiples
• Implied Price Per Share
• Ownership Activity/ Insider Trades
• Ownership Summary
• An analysis of ESG Risk Rating
• Key Professionals
• Key Board Members
• Key Risks Considerations
• Analyst Ratings
• Analyst Industry Views
• Disclosures
BioMarin Pharmaceutical Inc: VOXZOGO’s Global Expansion and Lifecycle Innovation Define the Growth Arc — What’s the Pipeline Impact, Valuation Outlook & its 5 Key Catalysts ?
BioMarin’s Q1 FY25 print affirms its operational maturity, with 15% YoY revenue growth to $745M and a 59% EPS surge to $1.13 driven by margin expansion and productivity gains from its BU model shift. VOXZOGO grew 40% YoY to $214M, with global market breadth and younger patient uptake setting the stage for H2 reacceleration. Enzyme therapies delivered solid 8% growth, led by PALYNZIQ (+22%) and ALDURAZYME (+40%), reinforcing the segment’s cash-generative stability. Management’s focus on adolescent label expansion and PKU quality-of-life endpoints highlights long-term commercial depth. Operational leverage was evident, with >1,000bps OM expansion and +271% YoY operating cash flow, as spend was funneled into high-return initiatives. VOXZOGO lifecycle growth through hypochondroplasia (Phase III data in 2026), BMN 351 (DMD biopsy readout in 2H25), and BMN 333 (long-acting CNP PK data) provide critical near-term inflection points. Meanwhile, policy and tariff risks are de minimis due to global footprint and payer mix. The company’s disciplined BD stance, with an expected 2025 deal, could enhance its post-2027 growth narrative. With margin durability, global expansion, and pipeline optionality converging, BioMarin enters a structurally advantaged phase. Can successful execution on BMN 351 and BMN 333 milestones cement BioMarin’s leadership beyond VOXZOGO and re-rate investor confidence into FY26?
